Showing 4921-4930 of 6036 results for "".
- Mount Sinai Ophthalmologists use Breakthrough Imaging to Understand Eye Damage from Rare Congenital Retinal Diseasehttps://modernod.com/news/mount-sinai-ophthalmologists-use-breakthrough-imaging-to-understand-eye-damage-from-rare-congenital-retinal-disease/2479098/Researchers from New York Eye and Ear Infirmary of Mount Sinai used adaptive optics–retinal imaging technology that allows clinicians to examine microscopic structures of the eye in living patients with extreme detail in real time–to analyze and better understand a rare retinal disease called “fu
- MIPT and Harvard Researchers Grow Stem Cells to Cure Glaucoma in Micehttps://modernod.com/news/mipt-and-harvard-researchers-grow-stem-cells-to-cure-glaucoma-in-mice/2479095/A joint research carried out by MIPT scientists and Harvard researchers have presented retinal cells that can integrate into the retina. This is the first successful attempt to transplant ganglion cells (retinal neurons that are destroyed by glaucoma) derived from stem cells in a lab setting. Sci
- Next-Generation COVID Vaccines Have Many Different Targetshttps://modernod.com/news/next-generation-covid-vaccines-have-many-different-targets/2479094/Vaccine developers are monitoring the durability of the immune response of current COVID vaccines while racing against variants to provide more options for protection, no matter what happens next in the pandemic, according to a Medscape report
- Nanodropper Completes $1.4 Million Seed Funding Roundhttps://modernod.com/news/nanodropper-completes-1-4-million-seed-funding-round/2479092/Nanodropper, which is making a first-of-its-kind eyedrop bottle adaptor that reduces eyedrop size, recently completed a $1.4 million seed round. Golden Seeds, a recognized leader in the movement to accelerate funding to women en
- Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/gyroscope-therapeutics-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2479087/Gyroscope Therapeutics announced it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) in the United States. All American Depositary Shares (ADSS) to be sold in the proposed IPO will be
- Katena Products Acquires Ophthalmic Instrument Maker Asicohttps://modernod.com/news/katena-products-acquires-ophthalmic-instrument-maker-asico/2479080/Katena Products announced it has purchased ophthalmic surgical instrument maker Asico. Terms of the deal were not disclosed Asico’s product range encompasses more 1,500 items, including stainless steel and titanium instruments, single-use cannulas and blades, and diamond knives.
- Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of Investigational Glaucoma Drug QLS-101https://modernod.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/Qlaris Bio announced the enrollment of the first patient in the phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower IOP by reducing episcleral venous pressure (EVP) in individuals with glaucoma. QLS-101 is a novel adenosine triphosphate (ATP)-sensitive pota
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize
- National Optometric Association to Host Regional Meeting at Vision Expo East 2021https://modernod.com/news/national-optometric-association-to-host-regional-meeting-at-vision-expo-east-2021/2479076/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announce that the National Optometric Association (NOA), an organization dedicated to advancing the visual health of minority populations through the delivery of effective and efficient eye and vision ca
- Alcon Canada Introduces UV Only IOLs for AcrySof IQ PanOptix and AcrySof IQ Vivity Portfolioshttps://modernod.com/news/alcon-canada-introduces-uv-only-iols-for-acrysof-iq-panoptix-and-acrysof-iq-vivity-portfolios/2479066/Alcon has announced the availability of AcrySof IQ PanOptix UV IOL, AcrySof IQ PanOptix Toric UV IOL, AcrySof IQ Vivity UV IOL, and AcrySof IQ Vivity Toric UV IOL as part of the presbyopia-correcting lens portfolio in Canada.1 These next-generation IOLs